Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST2)

August 23, 2011 updated by: Novartis Pharmaceuticals

A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1142

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
      • Gatineau, Canada
        • Novartis Investigator Site
      • Joliette, Canada
        • Novartis Investigator Site
      • Mirabel, Canada
        • Novartis Investigator Site
      • Mississauga, Canada
        • Novartis Investigator Site
      • Montreal, Canada
        • Novartis Investigator Site
      • Quebec, Canada
        • Novartis Investigative Site
      • Sainte-Foy, Canada
        • Novartis Investigator Site
      • Sherbrooke, Canada
        • Novartis Investigator Site
      • St-Jerome, Canada
        • Novartis Investigator Site
      • Toronto, Canada
        • Novartis Investigator Site
      • Trois-Rivières, Canada
        • Novartis Investigator Site
      • Windsor, Canada
        • Novartis Investigator Site
  • Colombia
      • Armenia, Colombia
        • Novartis Investigative Site
      • Barranquilla, Colombia
        • Novartis Investigator Site
      • Bogota, Colombia
        • Novartis Investigative Site
      • Cali, Colombia
        • Novartis Investigator Site
  • Czech Republic
      • Karlovy Vary, Czech Republic
        • Novartis Investigative Site
      • Kladno, Czech Republic
        • Novartis Investigative Site
      • Kromeriz, Czech Republic
        • Novartis Investigative Site
      • Liberec, Czech Republic
        • Novartis Investigative Site
      • Rokycany, Czech Republic
        • Novartis Investigative Site
      • Strakonice, Czech Republic
        • Novartis Investigative Site
      • Trebic, Czech Republic
        • Novartis Investigative Site
  • Hungary
      • Erd, Hungary
        • Novartis Investigative Site
      • Füzesabony, Hungary
        • Novartis Investigative Site
      • Gyor, Hungary
        • Novartis Investigator Site
      • Százhalombatta, Hungary
        • Novartis Investgative Site
  • India
      • Ahmedabad, India
        • Novartis Investigator Site
      • Bangalore, India
        • Novartis Investigator Site
      • Coimbatore, India
        • Novartis Investigator Site
      • Hyderabad, India
        • Novartis Investigative Site
      • Indore, India
        • Novartis Investigative Site
      • Jaipur, India
        • Novartis Investigative Site
      • Ludhiana, India
        • Novartis Investigator Site
      • Panjim, India
        • Novartis Investigative Site
      • Trivandrum, India
        • Novartis Investigator Site
  • Netherlands
      • Almelo, Netherlands
        • Novartis Investigative Site
      • Breda, Netherlands
        • Novartis Investigative Site
      • Heerlen, Netherlands
        • Novartis Investigative Site
      • Helmond, Netherlands
        • Novartis Investigative Site
      • Veldhoven, Netherlands
        • Novartis Investigative Site
      • Zutphen, Netherlands
        • Novartis Investigative Site
  • Slovakia
      • Banska Bystrica, Slovakia
        • Novartis Investigative Site
      • Bardejov, Slovakia
        • Novartis Investigative Site
      • Bratislava, Slovakia
        • Novartis Investigator Site
      • Bratislava, Slovakia
        • Novartis Investigative Site
      • Martin, Slovakia
        • Novartis Investigative Site
      • Poprad, Slovakia
        • Novartis Investigative Site
      • Povazska Bystrica, Slovakia
        • Novartis Investigative Site
      • Štúrovo, Slovakia
        • Novartis Investigative Site
  • Spain
      • Alicante, Spain
        • Novartis Investigative Site
      • Almeria, Spain
        • Novartis Investigative Site
      • Baracaldo, Spain
        • Novartis Investigative Site
      • Madrid, Spain
        • Novartis Investigator Site
      • Palma de Mallorca, Spain
        • Novartis Investigative Site
      • Pozuelo de Alarcón, Spain
        • Novartis Investigator Site
      • Riudecols, Spain
        • Novartis Investigator Site
      • San Boi De Llobregat, Spain
        • Novartis Investigative Site
      • Sevilla, Spain
        • Novartis Investigator Site
      • Vilassar de Mar, Spain
        • Novartis Investigative Site
  • United States
    • Alabama
      • Anniston, Alabama, United States, 36207-5710
        • Novartis Investigator Site
      • Birmingham, Alabama, United States, 35249-2181
        • Novartis Investigator Site
      • Jasper, Alabama, United States, 35501
        • Novartis Investigator Site
      • Mobile, Alabama, United States, 36608-1128
        • Novartis Investigator Site
    • Arizona
      • Glendale, Arizona, United States, 85306
        • Novartis Investigator Site
      • Phoenix, Arizona, United States, 85006
        • Novartis Investigator Site
      • Phoenix, Arizona, United States, 85013
        • Novartis Investigator Site
      • Scottsdale, Arizona, United States, 85251
        • Novartis Investigator Site
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Novartis Investigator Site
    • California
      • Buena Park, California, United States, 90620
        • Novartis Investigator Site
      • Fullerton, California, United States, 92835
        • Novartis Investigator Site
      • Mission Viejo, California, United States, 92691
        • Novartis Investigator Site
      • San Ramon, California, United States, 94583
        • Novartis Investigator Site
      • Santa Barbara, California, United States, 93110
        • Novartis Investigator Site
      • Sepulveda, California, United States, 91343
        • Novartis Investigator Site
      • Spring Valley, California, United States, 91978
        • Novartis Investigator Site
      • Torrance, California, United States, 90505
        • Novartis Investigator Site
      • Torrance, California, United States, 90502
        • Novartis Investigator Site
      • Vista, California, United States, 92083
        • Novartis Investigator Site
    • Colorado
      • Boulder, Colorado, United States, 80304
        • Novartis Investigator Site
      • Centennial, Colorado, United States, 80112
        • Novartis Investigator Site
      • Colorado Springs, Colorado, United States, 80907
        • Novartis Investigator Site
      • Denver, Colorado, United States, 80206
        • Novartis Investigator Site
    • Connecticut
      • Glastonbury, Connecticut, United States, 06033
        • Novartis Investigative Site
      • Waterbury, Connecticut, United States, 06708
        • Novartis Investigative Site
    • Florida
      • Clearwater, Florida, United States, 33765
        • Novartis Investigator Site
      • Destin, Florida, United States, 32541
        • Novartis Investigator Site
      • Maitland, Florida, United States, 32751
        • Novartis Investigator Site
      • Miami, Florida, United States, 33125
        • Novartis Investigator Site
      • Miami Beach, Florida, United States, 33140
        • Novartis Investigator Site
      • Ocala, Florida, United States, 34471
        • Novartis Investigator Site
      • Pensacola, Florida, United States, 32503
        • Novartis Investigator Site
      • Pensacola, Florida, United States, 32504
        • Novartis Investigator Site
      • Pensacola, Florida, United States, 32514
        • Novartis Investigator Site
      • Port Orange, Florida, United States, 32127
        • Novartis Investigator Site
      • South Miami, Florida, United States, 33143
        • Novartis Investigator Site
      • Tamarac, Florida, United States, 33321
        • Novartis Investigator Site
      • Tampa, Florida, United States, 33603
        • Novartis Investigator Site
      • Tampa, Florida, United States, 33613
        • Novartis Investigator Site
    • Idaho
      • Couer D'Alene, Idaho, United States, 98314
        • Novartis Investigator Site
    • Illinois
      • Downers Grove, Illinois, United States, 60515
        • Novartis Investigator Site
      • Elk Grove Village, Illinois, United States, 60007
        • Novartis Investigator Site
      • River Forest, Illinois, United States, 60305
        • Novartis Investigator Site
      • Springfield, Illinois, United States, 62781
        • Novartis Investigator Site
    • Kansas
      • Shawnee, Kansas, United States, 66217
        • Novartis Investigator Site
    • Kentucky
      • Crescent Springs, Kentucky, United States, 41017
        • Novartis Investigator Site
      • Lexington, Kentucky, United States, 40504
        • Novartis Investigator Site
      • Louisville, Kentucky, United States, 40202
        • Novartis Investigator Site
    • Louisiana
      • Shreveport, Louisiana, United States, 71103
        • Novartis Investigator Site
    • Maryland
      • Waldorf, Maryland, United States, 20602
        • Novartis Investigative Site
    • Massachusetts
      • Burlington, Massachusetts, United States, 01803
        • Novartis Investigative Site
    • Michigan
      • Troy, Michigan, United States, 48085
        • Novartis Investigator Site
    • Minnesota
      • Chaska, Minnesota, United States, 55318
        • Novartis Investigator Site
      • Edina, Minnesota, United States, 55435
        • Novartis Investigator Site
      • Minneapolis, Minnesota, United States, 55402
        • Novartis Investigative Site
      • Rochester, Minnesota, United States, 55905
        • Novartis Investigator Site
      • St Paul, Minnesota, United States, 55130
        • Novartis Investigator Site
    • Missouri
      • Columbia, Missouri, United States, 65212
        • Novartis Investigator Site
      • Kansas City, Missouri, United States, 64128
        • Novartis Investigator Site
      • Ozark, Missouri, United States, 65721
        • Novartis Investigator Site
      • St. Louis, Missouri, United States, 63141
        • Novartis Investigator Site
      • St. Louis, Missouri, United States, 63110
        • Novartis Investigator Site
      • St. Louis, Missouri, United States, 63317
        • Novartis Investigator Site
    • Montana
      • Billings, Montana, United States, 59102
        • Novartis Investigator Site
      • Kalispell, Montana, United States, 59901
        • Novartis Investigator Site
    • Nebraska
      • Bellevue, Nebraska, United States, 68005
        • Novartis Investigator Site
      • Lincoln, Nebraska, United States, 68516
        • Novartis Investigator Site
      • Papillion, Nebraska, United States, 68046
        • Novartis Investigator Site
    • Nevada
      • Henderson, Nevada, United States, 89014
        • Novartis Investigator Site
    • New Jersey
      • Brick, New Jersey, United States, 08723
        • Novartis Investigative Site
      • New Brunswick, New Jersey, United States, 08902
        • Novartis Investigative Site
      • Ocean, New Jersey, United States, 07712
        • Novartis Investigative Site
    • New York
      • Bayside, New York, United States, 11361
        • Novartis Investigative Site
      • Great Neck, New York, United States, 11023
        • Novartis Investigative Site
      • Larchmont, New York, United States, 10538
        • Novartis Investigative Site
    • North Carolina
      • Burlington, North Carolina, United States, 27215
        • Novartis Investigative Site
      • Charlotte, North Carolina, United States, 28207
        • Novartis Investigator Site
      • Charlotte, North Carolina, United States, 28277
        • Novartis Investigator Site
      • Raleigh, North Carolina, United States, 27607
        • Novartis Investigative Center
      • Shelby, North Carolina, United States, 28150
        • Novartis Investigative Site
      • Statesville, North Carolina, United States, 28625
        • Novartis Investigator Site
      • Winston Salem, North Carolina, United States, 27103
        • Novartis Investigative Site
    • North Dakota
      • Fargo, North Dakota, United States, 58103
        • Novartis Investigator Site
      • Grand Forks, North Dakota, United States, 58201
        • Novartis Investigator Site
    • Ohio
      • Akron, Ohio, United States, 44313
        • Novartis Investigative Site
      • Cincinnati, Ohio, United States, 45231
        • Novartis Investigator Site
      • Cincinnati, Ohio, United States, 45242
        • Novartis Investigator Site
      • Cleveland, Ohio, United States, 44109
        • Novartis Investigator Site
      • Toledo, Ohio, United States, 43608
        • Novartis Investigator Site
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Novartis Investigator Site
    • Oregon
      • Eugene, Oregon, United States, 97401
        • Novartis Investigator Site
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Novartis Investigative Site
      • Beaver, Pennsylvania, United States, 15009
        • Novartis Investigative Site
      • Erie, Pennsylvania, United States, 16506
        • Novartis Investigative Site
      • Philadelphia, Pennsylvania, United States, 19104
        • Novartis Investigative Site
      • Philadelphia, Pennsylvania, United States, 19140
        • Novartis Investigative Site
      • Phoenixville, Pennsylvania, United States, 19460
        • Novartis Investigative Site
    • Rhode Island
      • Pawtucket, Rhode Island, United States, 02860
        • Novartis Investigative Site
      • Providence, Rhode Island, United States, 02903
        • Novartis Investigative Site
    • South Carolina
      • Charleston, South Carolina, United States, 29407
        • Novartis Investigator Site
      • Easley, South Carolina, United States, 26940
        • Novartis Investigator Site
      • Greenville, South Carolina, United States, 29615
        • Novartis Investigator Site
      • North Charleston, South Carolina, United States, 29406-7108
        • Novartis Investigator Site
      • Spartanburg, South Carolina, United States, 29303
        • Novartis Investigator Site
      • Union, South Carolina, United States, 29379
        • Novartis Investigator Site
    • Texas
      • Dallas, Texas, United States, 75246
        • Novartis Investigator Site
      • Dallas, Texas, United States, 75216
        • Novartis Investigator Site
      • Fort Worth, Texas, United States, 76109
        • Novartis Investigator Site
      • Houston, Texas, United States, 77030
        • Novartis Investigator Site
      • Tyler, Texas, United States, 75708
        • Novartis Investigator Site
    • Utah
      • Salt Lake City, Utah, United States, 84107
        • Novartis Investigator Site
    • Virginia
      • Abingdon, Virginia, United States, 24210
        • Novartis Investigative Site
      • Fredericks, Virginia, United States, 22401
        • Novartis Investigative Site
    • Washington
      • Renton, Washington, United States, 98055
        • Novartis Investigator Site
      • Spokane, Washington, United States, 99204
        • Novartis Investigator Site
    • West Virginia
      • Morgantown, West Virginia, United States, 26505
        • Novartis Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:

    • Smoking history of at least 10 pack-years
    • Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value
    • Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%

Exclusion Criteria:

  • Patients who have received systemic corticosteroids and/or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
  • Patients who have had a respiratory tract infection within 6 weeks prior to screening
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions

Other protocol-defined inclusion/exclusion criteria applied to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Indacaterol 150 μg and tiotropium 18 μg
Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Drug: Indacaterol 150 μg
Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Drug: Tiotropium 18 μg
Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
Active Comparator: Tiotropium 18 μg
Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Drug: Placebo to indacaterol
Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Drug: Tiotropium 18 μg
Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of the Study (Week 12, Day 84)
Time Frame: From 5 minutes to 8 hours post-dose at the end of the study (Week 12, Day 84)
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose at the end of the study (Week 12, Day 84). The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 8 hours post-dose at the end of the study (Week 12, Day 84)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2
Time Frame: 24 hours post-dose on Day 2
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 2. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
24 hours post-dose on Day 2
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)
Time Frame: End of the study (Week 12 + 1 day, Day 85)
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of the study. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
End of the study (Week 12 + 1 day, Day 85)
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose on Day 1
Time Frame: From 5 minutes to 8 hours post-dose on Day 1
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 8 hours post-dose on Day 1
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose on Day 1
Time Frame: From 5 minutes to 4 hours post-dose on Day 1
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose on Day 1. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 4 hours post-dose on Day 1
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of the Study (Week 12, Day 84)
Time Frame: From 5 minutes to 4 hours post-dose at the end of the study (Week 12, Day 84)
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose at the end of the study (Week 12, Day 84). The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
From 5 minutes to 4 hours post-dose at the end of the study (Week 12, Day 84)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novartis Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2009

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2010

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2010

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 6, 2009

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2009

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 7, 2009

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 25, 2011

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 23, 2011

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CQAB149B2351

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings